Separately, Maxim Group set a $8.00 price target on shares of TrovaGene and gave the company a “buy” rating in a research report on Thursday, May 23rd.
PAVM stock traded down $0.01 on Friday, hitting $1.05. 296,600 shares of the company’s stock traded hands, compared to its average volume of 277,235. PAVmed has a 1-year low of $0.86 and a 1-year high of $1.70. The stock’s fifty day moving average is $1.11.
In other news, CEO Lishan Aklog purchased 30,000 shares of PAVmed stock in a transaction that occurred on Thursday, May 23rd. The stock was acquired at an average price of $1.10 per share, for a total transaction of $33,000.00. Following the transaction, the chief executive officer now owns 848,413 shares in the company, valued at $933,254.30. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 34.40% of the stock is currently owned by corporate insiders.
PAVmed Company Profile
PAVmed Inc operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive cell collection device and DNA biomarkers to detect esophageal cancer precursor; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube.
Featured Article: Technical Analysis of Stocks and What It Means
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.